HIGHLIGHTS
- who: Ling Ding and collaborators from the Institut University, Hangzhou, China, have published the research: Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling Zhejiang Province Key, in the Journal: (JOURNAL) of September/15,/2020
- what: The authors report that the antidiabetes drug canagliflozin suppresses tumor growth by reducing the expression of PD-L1 in an on-target manner. The injection of CD34+ stem_cells into newborn or young mice, also known as the Hu-SRC-SCID model, allows for the differentiation and development of a more complete immune system, including T_cells, B . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.